Key Takeaways
- Revenue up ~20%, margins lag: Q1 revenue grew 19.5% to ~₹560 crore, driven by herbicides and new products, but EBITDA rose only ~10.5% because the higher-margin Maharatna portfolio did not move as expected in a herbicide-heavy quarter.
- Export target cut on currency chaos: The full-year export target was lowered to ₹150 crore from ₹200 crore as dollar shortages and currency depreciation in developing markets forced buyers into smaller, hesitant orders.
- Product portfolio reshaped for margin: The company classified its range into Focused Maharatnas, Maharatnas, Gold, and Silver tiers, aiming to concentrate two-thirds of market share in the top two higher-margin buckets while cutting tail products.
- Two plants nearing completion: The Chopanki plant starts full operations in August and the Dahej SEZ expansion is now expected around Diwali, delayed roughly one month by heavy Gujarat rains.
- What to watch next quarter: Whether Q2 EBITDA margin expands the promised ~100 bps as the insecticide season brings better Maharatna mix, and whether August revenue holds at July levels to beat last year's Q2 in two months alone.
Revenue Performance & Seasonal Dynamics
- Herbicide-led quarter: Q1 growth came primarily from herbicides, with the season extending in certain areas; new-generation formulations Hachiman (first full year) and Torry drove volume, while some non-focused products lost volume.
- Price and volume split: Price hikes contributed 7–8% of the 19.5% growth, with the majority coming from volume and value increase in focused products.
- Monsoon disruption: Delayed monsoons followed by continuous rains destroyed some crops, forced re-sowing in areas, and caused sprays to be delayed or lost entirely, but full dams and canals give good hope for the upcoming season.
- Market recovery vs last year: Last year August was 50% of July and September was 50% of August; this year management expects August to touch July figures, which would mean beating last year's Q2 in two months alone.
- B2B growth as a byproduct: B2B sales are growing because new launches involve chemistries other companies want, though the primary target of launches remains B2C.
Rajesh Aggarwal: "Last year it was very bad situation in this period. Generally, the month of August is almost similar to the month of July. But last year it was 50% off July... This year, I believe that we will be touching July figures actually in the month of August. If we are able to do that then we should be able to beat the last year in two months itself, last year Q2 in two months itself."
Margin Structure & Product Portfolio Strategy
- Q1 margin drag: EBITDA margin compressed because Q1 is primarily a herbicide season and the movement of Maharatnas and Focused Maharatnas, which carry higher margins, was not to the desired extent.
- Portfolio restructuring: Products were divided into Focused Maharatnas (11 products), Maharatnas (~20), Gold (30–40), and Silver (~50 tail-cutting products) to focus the salesforce and market on higher-margin, new-generation green-technology products.
- Tail-cutting policy: The company is discontinuing products that are losing share and working on new technologies to improve margins, with a continuous goal of adding ~100 bps year-on-year, though management cautioned this is not guaranteed to be sustainable year on year.
- Product freshness index: The index is not meaningful in Q1 because the herbicide market comes first, followed by insecticide and fungicide; the mix will change in totality in Q2.
- Partner strategy by product type: For Japanese partnership patented products like Hachiman and Izuki, the company will be very choosy, adding only 1–2 partners year-on-year; for generic first-time-in-India technologies like Torry, Supremo, and Stunner, it will add 2–4 partners over two years.
Rajesh Aggarwal: "It is our continuous goal of increasing the margins by 100 bps year on year. I'll not say that 100 bps will be sustainable year on year."
Export Challenges
- Target cut: The full-year export target was toned down to ₹150 crore from the original ₹200 crore, though management still expects to cross last year's ~₹130–140 crore.
- Currency and payment crisis: Currencies worldwide have deteriorated and countries lack dollars to pay; LCs are not being honored, ECGC is cutting limits, and bankers are reducing approved bank lists across Africa, the Middle East, and South America.
- Pricing squeeze: Currency depreciation in developing countries has been worse than INR depreciation, making it difficult to sell at required prices; buyers avoid big orders due to price inconsistency and are converting to smaller consignments.
- Seasonal pattern intact: Q1 is traditionally subtle for exports; the first half is the domestic market and the second half is international markets.
- Long-term potential: Management sees very huge potential in years to come, exporting both chemical and biological segments, and is investing heavily in data generation including impurity profiling via GLP accreditation.
Rajesh Aggarwal: "The currency worldwide has deteriorated too much and the countries do not have the dollars to pay. So, this has slowed down our exports because people are shaking to avoid the -- they're avoiding to place a big order because of the non-consistency of price or the heavy price increase and they are converting these big orders into small, small orders."
New Products & Innovation Pipeline
- Recent launches gaining traction: Hachiman (soybean) got very good response in Q1 and Q2; Kunoichi and Oxim are doing fine with demand expected in later seasons; Torry (herbicide for corn) received very good success with 2–3 partners.
- Q2 launch slate: Three products planned for Q2: Izuki (fungicide mixture from Nissan and Hakko chemicals, for rice), Supremo, and Stunner.
- Full-year launch target: 8–9 new products targeted this year, subject to registration timelines which are tough and prone to delays.
- JV new-discovery timeline: The first product from the JV is expected by 2025 or 2026, with the majority of the 2–3 products in the pipeline coming by 2030; new discoveries take 3–4 years after patent, and products take 4–5 years after patent to launch.
- Patent progress: The company bagged a few patents this quarter from the JV and other R&D centers; total filings exceed 32, with about half received.
- Biologicals subsidiary: IIL Biologicals Limited is being set up as a 100% owned subsidiary, with business targeted to start next fiscal; scientists are developing products and some range is already in the market via outsourcing.
- Crop expansion: The company is becoming more aggressive on maize, sugarcane, vegetables, fruits, flowers, and soyabean via new products.
Rajesh Aggarwal: "Companies worldwide claim that one new discovery takes more than INR 1000 crore to launch and this type of time, we have set up this JV in 2013 and we are sitting in 2023, already 10 years are gone. I'll be launching my first product by 2025 or '26 and majority of the products, two, three products which are there in line they will come by 2030."
Capacity Expansion & CapEx
- Chopanki plant: Almost complete; partial activities have started and full operations are expected to begin in August, bringing more technicals and capacity increases.
- Dahej SEZ plant: The SEZ plant is completed and a major expansion in the technical plant is underway; originally targeted for September completion, it is now delayed by roughly one month due to heavy rains in Gujarat, with operations expected to start around Diwali (October).
- New technical manufacturing: Timbor technical has already started at Dahej; Stunner technical will also come from Dahej; Supremo and Stunner will be launched from these new technicals.
- Full-year CapEx: Approximately ₹30–40 crore, largely for pending Dahej work and some Chopanki.
- JV pilot plants: Small plants to be set up mostly in Dahej, with initial expense of ₹20–30 crore per annum funded from internal accruals; both parent companies must contribute their share annually.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q2 revenue growth | Beat Q1 growth (20%+) | Q2 FY23 |
| Q2 EBITDA margin | Increase of ~100 bps, driven by better Maharatna mix | Q2 FY23 |
| Full-year EBITDA margin | Increase of ~100 bps for the year as a whole | FY23 |
| Full-year revenue growth | 18–20% | FY23 |
| Export revenue | ₹150 crore (toned down from ₹200 crore), crossing last year's ~₹130–140 crore | FY23 |
| Chopanki plant | Full operations starting | August |
| Dahej plant expansion | Operations starting around Diwali (delayed ~1 month from September) | October |
| Q2 product launches | Izuki, Supremo, Stunner (3 products) | Q2 FY23 |
| Full-year product launches | 8–9 new products, subject to registration timelines | FY23 |
| JV first new-discovery product | First product launch | 2025 or 2026 |
| JV majority pipeline products | 2–3 products to launch | By 2030 |
| IIL Biologicals subsidiary | Business to start | Next fiscal |
| Full-year CapEx | Approximately ₹30–40 crore | FY23 |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹560 cr, +19.5% YoY |
| EBITDA | ₹58 cr, +10.5% YoY |
| Revenue growth | 19.5%, driven by new product launches and volume growth; price hike contributed 7–8% |
| EBITDA margin guidance (Q2 FY23) | +100 bps targeted improvement over Q2 FY22 |
| EBITDA margin guidance (full year FY23) | +100 bps targeted improvement, though not sustainable year on year |
| Export revenue target (full year FY23) | ₹150 cr, toned down from original ₹200 cr target due to international challenges; last year exports were ₹130–140 cr |
| Full-year revenue growth target | 20% |
| CapEx (full year FY23) | ₹30–40 cr, primarily for Dahej and Chopanki plant completions |
| Focused Maharatnas products | 11 products, part of a 35-product Maharatnas range contributing 65% of brand revenue |
| Products crossing ₹50 cr revenue (FY23) | More than half a dozen products expected |
| New product launches planned (FY23) | 8–9 products; 2 launched in Q1 (Torry, Shinwa), 3 planned for Q2 (Izuki, Supremo, Stunner) |
| Patents filed | More than 32 filed, approximately half received |
| GLP accreditation | 52nd in India across all sectors |